EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40 13-Jun-2025 / 10:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA AG: Merger...
EQS-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement/Quarter Results APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025 15.05.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025 Group sales rise to EUR 12.9 million in Q1 2025 (3M 2024: EUR 10.0 million) Single Pill combinations grew strongly overall...
EQS-News: APONTIS PHARMA AG / Key word(s): Annual Report/Annual Results APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned 31.03.2025 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned Sales increases significantly to EUR 48.5 million in 2024 financial year (2023: EUR 37.0...
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger squeeze-out of the minority shareholders of APONTIS PHARMA AG – merger agreement planned 05-March-2025 / 20:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Publication of inside...
EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived 21.11.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived Zentiva waives the condition of minimum acceptance Acceptance Period ends unchanged today, 21 November 2024 at 24:00 CET Around 60% of...
EQS-News: APONTIS PHARMA AG / Key word(s): 9 Month figures/Change in Forecast APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted 07.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023:...
EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer/Statement Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer 30.10.2024 / 16:20 CET/CEST The issuer is solely responsible for the content of this announcement. Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer Joint reasoned statement by Management Board and Supervisory Board published Offer price of EUR 10.00 per share...
EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer 16.10.2024 / 11:55 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer APONTIS PHARMA and Zentiva signed an investment agreement today Growth strategy of...
